Compare IPCA Labs with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STERLING BIOTECH - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STERLING BIOTECH IPCA LABS/
STERLING BIOTECH
 
P/E (TTM) x 23.7 -0.4 - View Chart
P/BV x 4.5 0.0 31,781.6% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 IPCA LABS   STERLING BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-19
STERLING BIOTECH
Dec-13
IPCA LABS/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,04211 9,923.8%   
Low Rs5903 17,355.9%   
Sales per share (Unadj.) Rs298.626.8 1,114.0%  
Earnings per share (Unadj.) Rs35.0-15.0 -234.0%  
Cash flow per share (Unadj.) Rs49.4-5.5 -905.0%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.154.9 450.3%  
Shares outstanding (eoy) m126.35267.87 47.2%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.70.3 1,054.0%   
Avg P/E ratio x23.3-0.5 -5,017.8%  
P/CF ratio (eoy) x16.5-1.3 -1,297.4%  
Price / Book Value ratio x3.30.1 2,607.7%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,1081,862 5,538.4%   
No. of employees `00013.41.4 992.8%   
Total wages/salary Rs m7,874547 1,440.0%   
Avg. sales/employee Rs Th2,807.05,303.3 52.9%   
Avg. wages/employee Rs Th585.8403.8 145.1%   
Avg. net profit/employee Rs Th329.0-2,959.0 -11.1%   
INCOME DATA
Net Sales Rs m37,7327,181 525.5%  
Other income Rs m57743 1,354.0%   
Total revenues Rs m38,3097,223 530.3%   
Gross profit Rs m6,901947 728.8%  
Depreciation Rs m1,8242,543 71.7%   
Interest Rs m1894,377 4.3%   
Profit before tax Rs m5,465-5,931 -92.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042-1,924 -54.2%   
Profit after tax Rs m4,422-4,007 -110.4%  
Gross profit margin %18.313.2 138.7%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %11.7-55.8 -21.0%  
BALANCE SHEET DATA
Current assets Rs m23,77814,335 165.9%   
Current liabilities Rs m10,97549,809 22.0%   
Net working cap to sales %33.9-494.0 -6.9%  
Current ratio x2.20.3 752.8%  
Inventory Days Days104403 25.7%  
Debtors Days Days66171 38.6%  
Net fixed assets Rs m20,36855,432 36.7%   
Share capital Rs m253268 94.3%   
"Free" reserves Rs m30,97113,935 222.3%   
Net worth Rs m31,22414,701 212.4%   
Long term debt Rs m1,4099,478 14.9%   
Total assets Rs m45,50773,988 61.5%  
Interest coverage x30.0-0.4 -8,440.1%   
Debt to equity ratio x00.6 7.0%  
Sales to assets ratio x0.80.1 854.3%   
Return on assets %10.10.5 2,022.9%  
Return on equity %14.2-27.3 -52.0%  
Return on capital %17.3-6.4 -269.6%  
Exports to sales %45.925.9 177.1%   
Imports to sales %16.60.2 9,775.0%   
Exports (fob) Rs m17,3081,860 930.7%   
Imports (cif) Rs m6,26612 51,363.9%   
Fx inflow Rs m17,3081,860 930.7%   
Fx outflow Rs m6,26625 25,176.4%   
Net fx Rs m11,0421,835 601.8%   
CASH FLOW
From Operations Rs m4,9231,719 286.4%  
From Investments Rs m-1,563-3,148 49.7%  
From Financial Activity Rs m-1,8321,426 -128.5%  
Net Cashflow Rs m1,528-3 -44,932.4%  

Share Holding

Indian Promoters % 45.9 33.9 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 9.9 255.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.4 39.3 44.3%  
Shareholders   36,892 21,482 171.7%  
Pledged promoter(s) holding % 2.1 55.9 3.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Frauds at Public Sector Banks, Upcoming IPOs, and Top Cues in Focus Today(Pre-Open)

India share markets ended their volatile day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 76 points (down 0.2%).

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 21, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS